High-performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its demethyl metabolite in human plasma.
A validated HPLC method for the simultaneous quantitative analysis of the antidepressant mirtazapine and its demethyl metabolite in human plasma is described. The active constituents including internal standard were extracted from 1 ml of plasma with hexane and separated on a muBondapak Phenyl column with fluorescence detection. The lower limit of quantification was 0.5 ng/ml, without significant interferences with endogenous or exogenous components. Inter- and intra-assay accuracy determined at quality control levels of 2, 10 and 80 ng/ml were, respectively, 104.6-113.7% and 105.1-117.7% for mirtazapine, and 91.7-99.3% and 89.9-103.7% for demethylmirtazapine. In all cases the precision was below 6.8%.
Maris
F A
FA
Thiemann Arzneimittel GmbH, Waltrop, Germany.
Dingler
E
E
Niehues
S
S
D000929:Antidepressive Agents, Tricyclic / Q000097:blood* / Q000493:pharmacokinetics; D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D004355:Drug Stability; D006801:Humans; D007202:Indicators and Reagents; D008803:Mianserin / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D000078785:Mirtazapine; D011786:Quality Control; D012015:Reference Standards; D015203:Reproducibility of Results; D012997:Solvents; D013050:Spectrometry, Fluorescence
D000929:Antidepressive Agents, Tricyclic; D007202:Indicators and Reagents; D012997:Solvents; D008803:Mianserin; D000078785:Mirtazapine; C119256:demethylmirtazapine